New cancer drug SIG001 enters first human tests

NCT ID NCT07486700

Not yet recruiting Disease control Sponsor: Peking University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SIG001 (a biologic drug given intravenously)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors by determining a safe dose for further testing.
What could go wrong: This is a very early Phase 1 trial with only 66 participants, so the drug may not prove effective or safe. Side effects are unknown, and it is not yet a proven therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLAMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLAMS

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.